Millot, Frédéric <br/><br/>
Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Jul 2011 
 - 2827-32 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2010.32.7114  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antineoplastic Agents--adverse effects<br/>Benzamides<br/>Child<br/>Child, Preschool<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Drug-Related Side Effects and Adverse Reactions<br/>France<br/>Humans<br/>Imatinib Mesylate<br/>Infant<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Piperazines--adverse effects<br/>Prospective Studies<br/>Pyrimidines--adverse effects<br/>Survival Analysis